Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amicus Therapeutics
(NQ:
FOLD
)
10.50
+0.45 (+4.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amicus Therapeutics
< Previous
1
2
3
4
5
Next >
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
May 11, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
7 Biotech Stocks With Key Catalysts for May
May 11, 2022
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns.
Via
InvestorPlace
FDA Extends Review Of Amicus Therapeutics' AT-GAA For The Treatment Of Pompe Disease By Three Months
May 10, 2022
The U.S.
Via
Benzinga
Recap: Amicus Therapeutics Q1 Earnings
May 09, 2022
Amicus Therapeutics (NASDAQ:FOLD) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Amicus Shares Encouraging Long-Term Data Of AT-GAA Study In Pompe Disease
March 16, 2022
Amicus Therapeutics Inc (NASDAQ: FOLD) has
Via
Benzinga
Earnings Outlook For Amicus Therapeutics
May 06, 2022
Amicus Therapeutics (NASDAQ:FOLD) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Amicus...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
May 01, 2022
The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a...
Via
Benzinga
Amicus Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know
April 27, 2022
Amicus Therapeutics (NASDAQ:FOLD) will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
Gene Therapy Player Amicus Therapeutics Terminates SPAC Merger, Shares Fall
February 24, 2022
Amicus Therapeutics Inc (NASDAQ: FOLD) has terminated its plans to spin off its gene therapy assets, citing 'existing market conditions.' With "market...
Via
Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...
Via
Benzinga
Amicus Therapeutics Earnings Preview
February 23, 2022
Amicus Therapeutics (NASDAQ:FOLD) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 14, 2022
January 14, 2022
Upgrades According to Seaport Global, the prior rating for Lennar Corp (NYSE:
Via
Benzinga
10 Biggest Price Target Changes For Friday
January 14, 2022
Keybanc cut Robinhood Markets, Inc. (NASDAQ:HOOD...
Via
Benzinga
60 Biggest Movers From Yesterday
January 11, 2022
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) rose 40.7% to settle at $8.44 after the company...
Via
Benzinga
Mid-Afternoon Market Update: Dow Tumbles 250 Points; Zynga Shares Spike Higher
January 10, 2022
Toward the end of trading Monday, the Dow traded down 0.70% to 35,978 while the NASDAQ fell 0.93% to 14,796.51. The S&P also fell, dropping, 0.72% to 4,643.29. The U.S....
Via
Benzinga
Mid-Day Market Update: Nasdaq Dips 300 Points; Apria Shares Surge
January 10, 2022
Midway through trading Monday, the Dow traded down 1.23% to 35,787.07 while the NASDAQ fell 2.07% to 14,627.21. The S&P also fell, dropping, 1.52% to 4,605.95. The U.S. has...
Via
Benzinga
45 Stocks Moving In Monday's Mid-Day Session
January 10, 2022
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares climbed 71.5% to $5.88. Zynga Inc. (NASDAQ: ZNGA) gained 45.7% to $8.74 after the company announced it will be acquired...
Via
Benzinga
Amicus Therapeutics, inc (FOLD) Q3 2021 Earnings Call Transcript
November 09, 2021
FOLD earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Benzinga's Top Ratings Upgrades, Downgrades For November 15, 2021
November 15, 2021
Upgrades For Targa Resources Corp (NYSE:
Via
Benzinga
The Week In SPAC News - Sunday, Oct. 3
October 03, 2021
In SPAC news this week, Amicus Therapeutics announced its intent to sell its gene therapy unit to ARYA Sciences Acquisition Corp IV, a SPAC sponsored by Perceptive Advisors.
Via
Talk Markets
Perceptive Advisors-Backed SPAC To Acquire Amicus's Gene Therapy Business
September 29, 2021
Amicus Therapeutics Inc (NASDAQ: FOLD) has agreed to spin off its gene therapy business to Sciences Acquisition Corp IV (NASDAQ: ARYD) and launch genetic...
Via
Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
November 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...
Via
Benzinga
Why Are Amicus Therapeutics Shares Trading Higher Today?
September 29, 2021
The FDA has accepted for review Amicus Therapeutics Inc's (NASDAQ: FOLD) Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug...
Via
Benzinga
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
September 30, 2021
Upgrades For Cabot Oil & Gas Corp (NYSE:COG),...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
September 29, 2021
Gainers Geovax Labs (NASDAQ:GOVX) shares increased by 23.44% to $5.16 during Wednesday's pre-market session. The market value of their outstanding shares is at $32.6...
Via
Benzinga
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
September 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Tuesday's After-Market Session
September 07, 2021
Gainers Cellectar Biosciences (NASDAQ:CLRB
Via
Benzinga
Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?
August 12, 2021
One particular group of stocks is overrepresented among the exchange's biggest losers this year. That's an important detail.
Via
The Motley Fool
Amicus Therapeutics, inc (FOLD) Q2 2021 Earnings Call Transcript
August 05, 2021
FOLD earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Amicus's Fabry Disease Medicine Gets European Approval For Use In Adolescents
August 02, 2021
The European Commission has approved Amicus Therapeutics Inc (NASDAQ: FOLD) Galafold (migalastat) for use in adolescents with Fabry disease who have an amenable...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.